Hyungwon Moon
Hyungwon Moon has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Hyun Ryoung Kim
R&D Center, IMGT Co., Ltd., 172 Dolma-ro, Seongnam 13605, Republic of Korea
4 shared publications - Hak Jong Lee
Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Korea
3 shared publications - Ae Shin Cho
R&D Center, IMGT Co., Ltd., 172, Dolma-ro, Bundang-gu, Seongnam-si 13605, Gyeonggi-do, Korea
2 shared publications - Daehyun Kim
Department of Nano Science and Technology, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Korea
2 shared publications - Dongyeon Kim
Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea
2 shared publications - Seung Soo Lee
IMGT Co., Ltd., Seongnam 13605, Korea
2 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 302
Perfluoropentane Phase-Change Nanodroplets for Focused Ultrasound-Enhanced Drug Penetration and Immune Response
Background/Objectives: Solid tumors are characterized by a dense stromal structure and heterogeneous microenvironments that limit intratumoral drug penetration and contribute to immune exclusion. We developed perfluoropentane (PFP)-based phase-change nanodroplets (IMP700) and aimed to identify focused ultrasound (FUS) parameters that enhance cavitation and sonoporation to improve drug delivery and immune engagement in tumor models. Methods: IMP700 was prepared as lipid-shelled PFP nanodroplets and physicochemically characterized. Acoustic droplet vaporization (ADV), echogenicity, and cavitation were evaluated in vitro and in vivo using ultrasound imaging and cavitation analysis under varying FUS parameters, including acoustic intensity, duty cycle, and pulse repetition frequency (PRF), in PANC-1 xenograft tumors. Sonoporation was assessed by co-administering an ultrasound-responsive doxorubicin liposome (IMP301), and intratumoral drug distribution was analyzed by confocal imaging. Immune responses were evaluated in a syngeneic 4T1 tumor model by quantifying CD8+ T-cell infiltration after repeated treatments. Results: IMP700 exhibited nanoscale size and high PFP encapsulation efficiency and underwent ADV with increased echogenicity and intensity-dependent cavitation. In vivo, a 2% duty cycle and 10 Hz PRF produced strong and reproducible cavitation. Under these conditions, IMP700 markedly increased inertial cavitation and enhanced intratumoral drug penetration compared to FUS alone. Combined IMP700 and FUS treatment also increased intratumoral CD8+ T-cell infiltration. Conclusions: IMP700 amplifies FUS-induced cavitation, improves sonoporation-mediated drug delivery, and promotes CD8+ T-cell infiltration, which supports the use of FUS-activated nanodroplets as a strategy to overcome stromal and immunological barriers in solid tumors.
- 27 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 302
Open AccessPerfluoropentane Phase-Change Nanodroplets for Focused Ultrasound-Enhanced Drug Penetration and Immune Response
Background/Objectives: Solid tumors are characterized by a dense stromal structure and heterogeneous microenvironments that limit intratumoral drug penetration and contribute to immune exclusion. We developed perfluoropentane (PFP)-based phase-change nanodroplets (IMP700) and aimed to identify focused ultrasound (FUS) parameters that enhance cavitation and sonoporation to improve drug delivery and immune engagement in tumor models. Methods: IMP700 was prepared as lipid-shelled PFP nanodroplets and physicochemically characterized. Acoustic droplet vaporization (ADV), echogenicity, and cavitation were evaluated in vitro and in vivo using ultrasound imaging and cavitation analysis under varying FUS parameters, including acoustic intensity, duty cycle, and pulse repetition frequency (PRF), in PANC-1 xenograft tumors. Sonoporation was assessed by co-administering an ultrasound-responsive doxorubicin liposome (IMP301), and intratumoral drug distribution was analyzed by confocal imaging. Immune responses were evaluated in a syngeneic 4T1 tumor model by quantifying CD8+ T-cell infiltration after repeated treatments. Results: IMP700 exhibited nanoscale size and high PFP encapsulation efficiency and underwent ADV with increased echogenicity and intensity-dependent cavitation. In vivo, a 2% duty cycle and 10 Hz PRF produced strong and reproducible cavitation. Under these conditions, IMP700 markedly increased inertial cavitation and enhanced intratumoral drug penetration compared to FUS alone. Combined IMP700 and FUS treatment also increased intratumoral CD8+ T-cell infiltration. Conclusions: IMP700 amplifies FUS-induced cavitation, improves sonoporation-mediated drug delivery, and promotes CD8+ T-cell infiltration, which supports the use of FUS-activated nanodroplets as a strategy to overcome stromal and immunological barriers in solid tumors.
- Open Access
- 19 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 3
Ultrasound-Sensitive Liposomal Exatecan for Tumor-Specific Drug Release for Treatment of Pancreatic Cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, largely due to its dense stromal architecture and poor intratumoral drug penetration. To address this challenge, IMP305 was developed as an ultrasound-sensitive liposome for tumor-localized drug release. In particular, IMP305 is dominantly capable of release by ultrasound-mediated cavitation. Methods: This ultrasound-sensitive liposome integrates tumor-specific drug delivery with cavitation-induced loosening of the stromal architecture in PDAC, thereby enabling more efficient intratumoral drug release using PANC-1 xenografted mouse. Results: The maximal tolerance dose of exatecan was increased by encapsulation into IMP305. Cavitation-triggered structural disruption of IMP305 was 84.68 ± 6.21%, which resulted in a robust release of approximately 84.4 ± 1.95% of the encapsulated exatecan. In PANC-1 xenograft models, IMP305 exhibited a maximal tolerance dose approximately four times higher than that of free exatecan and demonstrated markedly superior antitumor ability. Especially, IMP305 combined with focused ultrasound achieved the most pronounced therapeutic benefit, demonstrating a 49.17 ± 9.00% reduction in tumor volume at day 48 and an 80% survival rate at day 60. Conclusions: In conclusion, these findings demonstrate that ultrasound-activated IMP305 significantly enhances intratumoral accumulation and release of exatecan, resulting in superior tumor suppression while mitigating systemic toxicity.
- 19 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 3
Open AccessUltrasound-Sensitive Liposomal Exatecan for Tumor-Specific Drug Release for Treatment of Pancreatic Cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, largely due to its dense stromal architecture and poor intratumoral drug penetration. To address this challenge, IMP305 was developed as an ultrasound-sensitive liposome for tumor-localized drug release. In particular, IMP305 is dominantly capable of release by ultrasound-mediated cavitation. Methods: This ultrasound-sensitive liposome integrates tumor-specific drug delivery with cavitation-induced loosening of the stromal architecture in PDAC, thereby enabling more efficient intratumoral drug release using PANC-1 xenografted mouse. Results: The maximal tolerance dose of exatecan was increased by encapsulation into IMP305. Cavitation-triggered structural disruption of IMP305 was 84.68 ± 6.21%, which resulted in a robust release of approximately 84.4 ± 1.95% of the encapsulated exatecan. In PANC-1 xenograft models, IMP305 exhibited a maximal tolerance dose approximately four times higher than that of free exatecan and demonstrated markedly superior antitumor ability. Especially, IMP305 combined with focused ultrasound achieved the most pronounced therapeutic benefit, demonstrating a 49.17 ± 9.00% reduction in tumor volume at day 48 and an 80% survival rate at day 60. Conclusions: In conclusion, these findings demonstrate that ultrasound-activated IMP305 significantly enhances intratumoral accumulation and release of exatecan, resulting in superior tumor suppression while mitigating systemic toxicity.
- Open Access
- 7 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1194
Development of a Polymersome-Based Nanomedicine for Chemotherapeutic and Sonodynamic Combination Therapy
In anticancer therapy, combination therapy has been suggested as an alternative to the insufficient therapeutic efficacy of single therapy. Among combination therapies, combination chemo- and photodynamic therapy are actively investigated. However, photodynamic therapy shows a limitation in the penetration depth of the laser. Therefore, sonodynamic therapy (SDT), using ultrasound instead of a laser as a trigger, is an upcoming strategy for deep tumors. Additionally, free drugs are easily degraded by enzymes, have difficulty in reaching the target site, and show side effects after systemic administration; therefore, the development of drug delivery systems is desirable for sufficient drug efficacy for combination therapy. However, nanocarriers, such as microbubbles, and albumin nanoparticles, are unstable in the body and show low drug-loading efficiency. Here, we propose polylactide (PLA)-poly (ethylene glycol) (PEG) polymersomes (PLs) with a high drug loading rate of doxorubicin (DOX) and verteporfin (VP) for effective combination therapy in both in vitro and in vivo experiments. The cellular uptake efficiency and cytotoxicity test results of VP-DOX-PLs were higher than that of single therapy. Moreover, in vivo biodistribution showed the accumulation of the VP-DOX-PLs in tumor regions. Therefore, VP-DOX-PLs showed more effective anticancer efficacy than either single therapy in vivo. These results suggest that the combination therapy of SDT and chemotherapy could show novel anticancer effects using VP-DOX-PLs.
- 7 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1194
Open AccessDevelopment of a Polymersome-Based Nanomedicine for Chemotherapeutic and Sonodynamic Combination Therapy
In anticancer therapy, combination therapy has been suggested as an alternative to the insufficient therapeutic efficacy of single therapy. Among combination therapies, combination chemo- and photodynamic therapy are actively investigated. However, photodynamic therapy shows a limitation in the penetration depth of the laser. Therefore, sonodynamic therapy (SDT), using ultrasound instead of a laser as a trigger, is an upcoming strategy for deep tumors. Additionally, free drugs are easily degraded by enzymes, have difficulty in reaching the target site, and show side effects after systemic administration; therefore, the development of drug delivery systems is desirable for sufficient drug efficacy for combination therapy. However, nanocarriers, such as microbubbles, and albumin nanoparticles, are unstable in the body and show low drug-loading efficiency. Here, we propose polylactide (PLA)-poly (ethylene glycol) (PEG) polymersomes (PLs) with a high drug loading rate of doxorubicin (DOX) and verteporfin (VP) for effective combination therapy in both in vitro and in vivo experiments. The cellular uptake efficiency and cytotoxicity test results of VP-DOX-PLs were higher than that of single therapy. Moreover, in vivo biodistribution showed the accumulation of the VP-DOX-PLs in tumor regions. Therefore, VP-DOX-PLs showed more effective anticancer efficacy than either single therapy in vivo. These results suggest that the combination therapy of SDT and chemotherapy could show novel anticancer effects using VP-DOX-PLs.
- Open Access
- 25 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2603
Evading Doxorubicin-Induced Systemic Immunosuppression Using Ultrasound-Responsive Liposomes Combined with Focused Ultrasound
Doxorubicin (DOX) is a representative anticancer drug with a unique ability to induce immunogenic cell death of cancer cells. However, undesired toxicity on immune cells has remained a significant challenge, hindering the usage of DOX in cancer immunotherapy. Here, we report a combined therapy to avoid the off-target toxicity of DOX by adapting ultrasound-responsive liposomal doxorubicin and focused ultrasound exposure. Histological analysis demonstrated that the combined therapy induced less hemosiderosis of splenocytes and improved tumor infiltration of cytotoxic T lymphocytes. Additionally, in vivo therapeutic evaluation results indicate that the combined therapy achieved higher efficacy when combined with PD-1 immune-checkpoint blockade therapy by improving immunogenicity.
- 25 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2603
Open AccessEvading Doxorubicin-Induced Systemic Immunosuppression Using Ultrasound-Responsive Liposomes Combined with Focused Ultrasound
Doxorubicin (DOX) is a representative anticancer drug with a unique ability to induce immunogenic cell death of cancer cells. However, undesired toxicity on immune cells has remained a significant challenge, hindering the usage of DOX in cancer immunotherapy. Here, we report a combined therapy to avoid the off-target toxicity of DOX by adapting ultrasound-responsive liposomal doxorubicin and focused ultrasound exposure. Histological analysis demonstrated that the combined therapy induced less hemosiderosis of splenocytes and improved tumor infiltration of cytotoxic T lymphocytes. Additionally, in vivo therapeutic evaluation results indicate that the combined therapy achieved higher efficacy when combined with PD-1 immune-checkpoint blockade therapy by improving immunogenicity.
- Open Access
- 21 July 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1512
Effects of Lipid Shape and Interactions on the Conformation, Dynamics, and Curvature of Ultrasound-Responsive Liposomes
We perform coarse-grained molecular dynamics simulations of bilayers composed of various lipids and cholesterol at their different ratios. Simulations show that cholesterol-lipid interactions restrict the lateral dynamics of bilayers but also promote bilayer curvature, indicating that these opposite effects simultaneously occur and thus cannot significantly influence bilayer stability. In contrast, lyso-lipids effectively pack the vacancy in the bilayer composed of cone-shaped lipids and thus reduce bilayer dynamics and curvature, showing that bilayers are more significantly stabilized by lyso-lipids than by cholesterol, in agreement with experiments. In particular, the bilayer composed of cone-shaped lipids shows higher dynamics and curvature than does the bilayer composed of cylindrical-shaped lipids. To mimic ultrasound, a high external pressure was applied in the direction of bilayer normal, showing the formation of small pores that are surrounded by hydrophilic lipid headgroups, which can allow the release of drug molecules encapsulated into the liposome. These findings help to explain experimental observations regarding that liposomes are more significantly stabilized by lyso-lipids than by cholesterol, and that the liposome with cone-shaped lipids more effectively releases drug molecules upon applying ultrasound than does the liposome with cylindrical-shaped lipids.
- 21 July 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1512
Open AccessEffects of Lipid Shape and Interactions on the Conformation, Dynamics, and Curvature of Ultrasound-Responsive Liposomes
We perform coarse-grained molecular dynamics simulations of bilayers composed of various lipids and cholesterol at their different ratios. Simulations show that cholesterol-lipid interactions restrict the lateral dynamics of bilayers but also promote bilayer curvature, indicating that these opposite effects simultaneously occur and thus cannot significantly influence bilayer stability. In contrast, lyso-lipids effectively pack the vacancy in the bilayer composed of cone-shaped lipids and thus reduce bilayer dynamics and curvature, showing that bilayers are more significantly stabilized by lyso-lipids than by cholesterol, in agreement with experiments. In particular, the bilayer composed of cone-shaped lipids shows higher dynamics and curvature than does the bilayer composed of cylindrical-shaped lipids. To mimic ultrasound, a high external pressure was applied in the direction of bilayer normal, showing the formation of small pores that are surrounded by hydrophilic lipid headgroups, which can allow the release of drug molecules encapsulated into the liposome. These findings help to explain experimental observations regarding that liposomes are more significantly stabilized by lyso-lipids than by cholesterol, and that the liposome with cone-shaped lipids more effectively releases drug molecules upon applying ultrasound than does the liposome with cylindrical-shaped lipids.
- Open Access
- 21 June 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1314
Ultrasound-Responsive Liposomes for Targeted Drug Delivery Combined with Focused Ultrasound
Chemotherapeutic drugs are traditionally used for the treatment of cancer. However, chemodrugs generally induce side effects and decrease anticancer effects due to indiscriminate diffusion and poor drug delivery. To overcome these limitations of chemotherapy, in this study, ultrasound-responsive liposomes were fabricated and used as drug carriers for delivering the anticancer drug doxorubicin, which was able to induce cancer cell death. The ultrasound-sensitive liposome demonstrated a size distribution of 81.94 nm, and the entrapment efficiency of doxorubicin was 97.1 ± 1.44%. The release of doxorubicin under the ultrasound irradiation was 60% on continuous wave and 50% by optimizing the focused ultrasound conditions. In vivo fluorescence live imaging was used to visualize the doxorubicin release in the MDA-MB-231 xenografted mouse, and it was demonstrated that liposomal drugs were released in response to ultrasound irradiation of the tissue. The combination of ultrasound and liposomes suppressed tumor growth over 56% more than liposomes without ultrasound exposure and 98% more than the control group. In conclusion, this study provides a potential alternative for overcoming the previous limitations of chemotherapeutics.
- 21 June 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1314
Open AccessUltrasound-Responsive Liposomes for Targeted Drug Delivery Combined with Focused Ultrasound
Chemotherapeutic drugs are traditionally used for the treatment of cancer. However, chemodrugs generally induce side effects and decrease anticancer effects due to indiscriminate diffusion and poor drug delivery. To overcome these limitations of chemotherapy, in this study, ultrasound-responsive liposomes were fabricated and used as drug carriers for delivering the anticancer drug doxorubicin, which was able to induce cancer cell death. The ultrasound-sensitive liposome demonstrated a size distribution of 81.94 nm, and the entrapment efficiency of doxorubicin was 97.1 ± 1.44%. The release of doxorubicin under the ultrasound irradiation was 60% on continuous wave and 50% by optimizing the focused ultrasound conditions. In vivo fluorescence live imaging was used to visualize the doxorubicin release in the MDA-MB-231 xenografted mouse, and it was demonstrated that liposomal drugs were released in response to ultrasound irradiation of the tissue. The combination of ultrasound and liposomes suppressed tumor growth over 56% more than liposomes without ultrasound exposure and 98% more than the control group. In conclusion, this study provides a potential alternative for overcoming the previous limitations of chemotherapeutics.
- Open Access
- 23 December 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (1) , 6
PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models
Cancer immunotherapy has revolutionized the way different neoplasms are treated. Among the different variations of cancer immunotherapy, the checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis have been validated and are currently used in the clinics. Nevertheless, these therapeutic antibodies are associated with significant side effects and are known to induce immune-related toxicities. To address these issues, we have developed an immune-microbubble complex (IMC) which not only reduces the toxicities associated with the antibodies but also enhances the therapeutic efficacy when combined with focused ultrasound. The concept of IMCs could be applied to any type of antibody-based treatment regimens to maximize their therapeutic potential.
- 23 December 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (1) , 6
Open AccessPD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models
Cancer immunotherapy has revolutionized the way different neoplasms are treated. Among the different variations of cancer immunotherapy, the checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis have been validated and are currently used in the clinics. Nevertheless, these therapeutic antibodies are associated with significant side effects and are known to induce immune-related toxicities. To address these issues, we have developed an immune-microbubble complex (IMC) which not only reduces the toxicities associated with the antibodies but also enhances the therapeutic efficacy when combined with focused ultrasound. The concept of IMCs could be applied to any type of antibody-based treatment regimens to maximize their therapeutic potential.
- Open Access
- 7 September 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 235
Combination Therapy with Doxorubicin-Loaded Reduced Albumin Nanoparticles and Focused Ultrasound in Mouse Breast Cancer Xenografts
Because chemotherapeutic drugs are often associated with serious side effects, the central topic in modern drug delivery is maximizing the localization of drugs at the target while minimizing non-specific drug interactions at unwanted regions. To address this issue, biocompatible nanoparticles have been developed to enhance the drug half-life while minimizing the associated toxicity. Nevertheless, relying solely on the enhanced half-life and enhanced permeability and retention (EPR) effects has been ineffective, and designing stimulus-sensitive nanoparticles to introduce the precise control of drug release has been desired. In this paper, we introduce a pH-sensitive, reduced albumin nanoparticle in combination with focused ultrasound treatment. Not only did these nanoparticles have superior therapeutic efficacy and toxicity profiles when compared to the free drugs in xenograft mouse models, but we were also able to show that the albumin nanoparticles reported in this paper were more suitable than other types of non-reduced albumin nanoparticles as vehicles for drug delivery. As such, we believe that the albumin nanoparticles presented in this paper with desirable characteristics including the induction of strong anti-tumor response, precise control, and superior safety profiles hold strong potential for preclinical and clinical anticancer therapy.
- 7 September 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 235
Open AccessCombination Therapy with Doxorubicin-Loaded Reduced Albumin Nanoparticles and Focused Ultrasound in Mouse Breast Cancer Xenografts
Because chemotherapeutic drugs are often associated with serious side effects, the central topic in modern drug delivery is maximizing the localization of drugs at the target while minimizing non-specific drug interactions at unwanted regions. To address this issue, biocompatible nanoparticles have been developed to enhance the drug half-life while minimizing the associated toxicity. Nevertheless, relying solely on the enhanced half-life and enhanced permeability and retention (EPR) effects has been ineffective, and designing stimulus-sensitive nanoparticles to introduce the precise control of drug release has been desired. In this paper, we introduce a pH-sensitive, reduced albumin nanoparticle in combination with focused ultrasound treatment. Not only did these nanoparticles have superior therapeutic efficacy and toxicity profiles when compared to the free drugs in xenograft mouse models, but we were also able to show that the albumin nanoparticles reported in this paper were more suitable than other types of non-reduced albumin nanoparticles as vehicles for drug delivery. As such, we believe that the albumin nanoparticles presented in this paper with desirable characteristics including the induction of strong anti-tumor response, precise control, and superior safety profiles hold strong potential for preclinical and clinical anticancer therapy.